Cite
HARVARD Citation
Galluzzo, M. et al. (2020). In which patients the best efficacy of secukinumab? Update of a real-life analysis after 136 weeks of treatment with secukinumab in moderate-to-severe plaque psoriasis. Expert opinion on biological therapy. pp. 173-182. [Online].